Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yissum Introduces a Pioneering Vaccine Against CME

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine.

Canine monocytic ehrlichiosis (CME) is a major, potentially fatal, tick-borne dog disease prevalent worldwide.

No commercial vaccine for the disease is currently available and tick control is the main preventive measure against the disease.

Now, Yissum Research and Development Company of the Hebrew University of Jerusalem, introduces a vaccine against CME, which was developed by Professors Shimon Harrus and Gad Baneth, from the Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences at the Hebrew University of Jerusalem.

The vaccine has proven effective in an experimental study in dogs, which was recently published in the prestigious journal Vaccine.

Profs. Harrus and Baneth developed the vaccine from a proprietary attenuated strain of Ehrlichia canis, the bacteria that causes CME. The efficiency of the attenuated strain as a vaccine was assessed on 12 dogs, which were divided into three groups.

Four dogs were inoculated (vaccinated) with the attenuated Ehrlichia strain twice, four dogs only once and the last group of four dogs served as the control group.

The vaccinated dogs showed no clinical signs after the inoculation, suggesting that the novel vaccine is safe for use and does not induce adverse effects.

When the dogs were infected with a virulent Ehrlichia field strain, the control dogs all developed a severe disease, whereas only three of the eight vaccinated dogs presented mild transient fever and the rest remained healthy.

"Canine monocytic ehrlichiosis is a serious dog disease that can lead to death. Current treatment includes supportive care, and a harsh and lengthy antibiotic treatment, which may not be effective in chronic infections. The vaccine developed by Profs. Harrus and Baneth is the first vaccine to prove effective against this disease," said Yaacov Michlin, CEO of Yissum.

Michlin continued, "The current lack of vaccine for CME, the growing awareness of the market and the growing market needs make this invention particularly attractive, and Yissum is currently looking for commercial partners for further development and commercialization purposes."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases
Novel technology utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs.
Saturday, August 08, 2015
ISA Scientific, Yissum, Hadasit and KIR to Collaborate
Licensing and collaboration agreement on treating diabetes and other serious health conditions with cannabidiol.
Friday, April 03, 2015
Yissum Introduces a Novel Method for Treating Cancer Based on Vif
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy.
Tuesday, July 10, 2012
Yissum to Collaborate with BioConnections
The novel kits enable direct detection of "superbugs" and provide instant guidelines for appropriate treatment.
Tuesday, February 28, 2012
Yissum Announces Long-Term Multi-Project Research and License Collaboration with Roche
Roche has selected six promising research projects for the treatment of metabolic diseases, initiated by Hebrew University researchers.
Monday, October 26, 2009
Yissum Licenses Stem Cell Technologies for Spinal Therapy to TheraCell
The technology will help to further develop and commercialize the technology for advanced regenerative medicine procedures.
Wednesday, July 15, 2009
Yissum Signs a Collaboration Agreement with Aurum Ventures MKI
Collaboration focuses on the development of liver-bypassing oral drug delivery nanotechnology.
Monday, June 29, 2009
Atox Bio and Fast-Track Drugs and Biologics Sign an R&D Collaboration Agreement
The collaboration is funded by the Israel-U.S. binational BIRD Foundation aimed at the development of therapeutics for sepsis and septic shock.
Thursday, June 25, 2009
Yissum Introduces Novel Compound for the Treatment of Osteoporosis
Hebrew University researchers have invented a new drug candidate that both inhibits bone resorption and stimulates bone formation.
Thursday, June 25, 2009
Z-Cube and Yissum Sign a Licensing Agreement for the Development of a Nanotechnology Drug Delivery System
Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for the treatment of pain.
Monday, June 01, 2009
Yissum Announces the Launch of the Hebrew University's Genetic Resource for Studies of Common Diseases
The Hebrew University Genetic Resource platform includes 15,000 DNA samples of Ashkenazi Jews.
Thursday, March 20, 2008
Yissum and Eucalyptus Collaborate to Develop Small Molecule for the Treatment of Neurodegenerative Diseases
The licensed molecule is an antioxidant that overcomes the blood-brain barrier.
Thursday, January 10, 2008
Yissum Spins-Off Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology
Nanolymf is dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.
Thursday, January 10, 2008
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!